Jelinek DF - Search Results

1

Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.

Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, Roos M, Laumann K, Ghosh AK, Lesnick C, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Shanafelt TD, et al. Among authors: jelinek df. Cancer. 2013 Jan 15;119(2):363-70. doi: 10.1002/cncr.27719. Epub 2012 Jul 3. Cancer. 2013. PMID: 22760587 Free PMC article. Clinical Trial.

2

Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.

Larsen JT, Shanafelt TD, Leis JF, LaPlant B, Call T, Pettinger A, Hanson C, Erlichman C, Habermann TM, Reeder C, Nikcevich D, Bowen D, Conte M, Boysen J, Secreto C, Lesnick C, Tschumper R, Jelinek D, Kay NE, Ding W. Larsen JT, et al. Am J Hematol. 2017 Aug;92(8):759-763. doi: 10.1002/ajh.24762. Epub 2017 Jun 1. Am J Hematol. 2017. PMID: 28402581 Free PMC article. Clinical Trial.

3

Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.

Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, Call T, Villalona-Calero M, Jelinek D, Bowen D, Laumann K, Wu W, Hanson C, Kay N. Shanafelt T, et al. Leuk Lymphoma. 2010 Dec;51(12):2222-9. doi: 10.3109/10428194.2010.524327. Epub 2010 Nov 5. Leuk Lymphoma. 2010. PMID: 21054149 Free PMC article. Clinical Trial.

4

VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.

Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. Lee YK, et al. Among authors: jelinek df. Blood. 2004 Aug 1;104(3):788-94. doi: 10.1182/blood-2003-08-2763. Epub 2004 Mar 2. Blood. 2004. PMID: 14996703 Free article.

5

Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.

Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW. Shanafelt TD, et al. Among authors: jelinek df. J Clin Oncol. 2006 Oct 1;24(28):4634-41. doi: 10.1200/JCO.2006.06.9492. J Clin Oncol. 2006. PMID: 17008705

6

Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test.

Nowakowski GS, Hoyer JD, Shanafelt TD, Geyer SM, LaPlant BR, Call TG, Jelinek DF, Zent CS, Kay NE. Nowakowski GS, et al. Among authors: jelinek df. Mayo Clin Proc. 2007 Apr;82(4):449-53. doi: 10.4065/82.4.449. Mayo Clin Proc. 2007. PMID: 17418074

7

Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.

Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE, Shanafelt TD. Maddocks-Christianson K, et al. Among authors: jelinek df. Br J Haematol. 2007 Nov;139(3):398-404. doi: 10.1111/j.1365-2141.2007.06801.x. Br J Haematol. 2007. PMID: 17910629 Free article.

8

Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.

Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, Nowakowski GS, Call TG, Dewald GW, Jelinek DF. Tschumper RC, et al. Among authors: jelinek df. J Clin Invest. 2008 Jan;118(1):306-15. doi: 10.1172/JCI32625. J Clin Invest. 2008. PMID: 18064298 Free PMC article.

9

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features.

Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Bowen DA, et al. Among authors: jelinek df. Leuk Lymphoma. 2007 Dec;48(12):2412-7. doi: 10.1080/10428190701724801. Leuk Lymphoma. 2007. PMID: 18067017

10

MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?

Shanafelt TD, Kay NE, Call TG, Zent CS, Jelinek DF, LaPlant B, Morice WG, Hanson CA. Shanafelt TD, et al. Among authors: jelinek df. Leuk Res. 2008 Sep;32(9):1458-61. doi: 10.1016/j.leukres.2007.11.030. Epub 2008 Jan 7. Leuk Res. 2008. PMID: 18179821 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

188 results

Search Page